乌鸦传媒

Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto

Small study suggests large benefit for Lu-177 dotatate in intracranial disease

Findings support PSMA PET in the preoperative workflow of intermediate- and high-risk tumors

But it may be able to deliver net carbon benefits, at least in radiology

Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients

Study shows twice as many locally advanced patients upstaged with PET-CT vs conventional staging

Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

Randomized study finds no meaningful difference in events of abnormalities between groups

Small increase in median PFS when combined with second-line chemotherapy

No overall risk increase in large meta-analysis, but higher risk seen for thyroid cancer

Increase in negative predictive value and improved sensitivity versus MRI alone

The debate continues in two dueling articles

PSMA-directed agent improved overall survival by median 4 months